NCT02299505
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02299505
Title Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult
Covered Countries USA | TUR | POL | NLD | LBN | ITA | GRC | GBR | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS

Facility Status City State Zip Country Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
Loma Linda University Loma Linda California 92354 United States Details
Goshen Center for Cancer Care IU Health - SC Indianapolis Indiana 46202 United States Details
Maryland Oncology Hematology, P.A. SC-2 Rockville Maryland 20850 United States Details
Essex Oncology of North Jersey PA SC Belleville New Jersey 07109 United States Details
Greenville Health System SC Greenville South Carolina 29615 United States Details
Utah Cancer Specialists Dept.of Utah Cancer Spec. (3) Salt Lake City Utah 84106 United States Details
Novartis Investigative Site Grafton Auckland Australia Details
Novartis Investigative Site Auckland Australia Details
Novartis Investigative Site Vienna 1210 Austria Details
Novartis Investigative Site Vienna A-1140 Austria Details
Novartis Investigative Site Edegem 2650 Belgium Details
Novartis Investigative Site Natal Rio Grande do Norte 59075 740 Brazil Details
Novartis Investigative Site Passo Fundo Rio Grande do Sul 99010-260 Brazil Details
Novartis Investigative Site Porto Alegre Rio Grande do Sul 90601-000 Brazil Details
Novartis Investigative Site Itajaí Santa Catarina 88301-229 Brazil Details
Novartis Investigative Site Barretos São Paulo 14784 400 Brazil Details
Novartis Investigative Site São Paulo São Paulo 01246 000 Brazil Details
Novartis Investigative Site Sofia 1303 Bulgaria Details
Novartis Investigative Site Edmonton Alberta T6G 1Z2 Canada Details
Novartis Investigative Site Hamilton Ontario L8V 5C2 Canada Details
Novartis Investigative Site Ottawa Ontario K1H 8L6 Canada Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Montería Colombia Details
Novartis Investigative Site Brno 65653 Czechia Details
Novartis Investigative Site Regensburg Bavaria 93053 Germany Details
Novartis Investigative Site Berlin 12351 Germany Details
Novartis Investigative Site Cologne 51109 Germany Details
Novartis Investigative Site Würzburg 97074 Germany Details
Novartis Investigative Site Athens GR 115 27 Greece Details
Novartis Investigative Site Athens GR14564 Greece Details
Novartis Investigative Site Hyderabad Andhra Pradesh 500 034 India Details
Novartis Investigative Site Bangalore Karnataka 560 095 India Details
Novartis Investigative Site Nashik Maharashtra 422002 India Details
Novartis Investigative Site Kolkata West Bengal 700063 India Details
Novartis Investigative Site Delhi 110 085 India Details
Novartis Investigative Site Bergamo BG 24127 Italy Details
Novartis Investigative Site Bologna BO 40138 Italy Details
Novartis Investigative Site Brescia BS 25123 Italy Details
Novartis Investigative Site Meldola FC 47014 Italy Details
Novartis Investigative Site San Giovanni Rotondo FG 71013 Italy Details
Novartis Investigative Site Milan MI 20141 Italy Details
Novartis Investigative Site Milan MI 20162 Italy Details
Novartis Investigative Site Aviano PN 33081 Italy Details
Novartis Investigative Site Roma RM 00155 Italy Details
Novartis Investigative Site Verona VR 37126 Italy Details
Novartis Investigative Site Novara 28100 Italy Details
Novartis Investigative Site El Achrafiyé Lebanon 166484 Lebanon Details
Novartis Investigative Site Kuching Sarawak 93586 Malaysia Details
Novartis Investigative Site Pulau Pinang 10990 Malaysia Details
Novartis Investigative Site Nieuwegein 3435 CM Netherlands Details
Novartis Investigative Site Gdansk 80 952 Poland Details
Novartis Investigative Site Konin 62 500 Poland Details
Novartis Investigative Site Tarnobrzeg 39-400 Poland Details
Novartis Investigative Site Saint Petersburg 197343 Russia Details
Novartis Investigative Site Seoul Korea 05505 South Korea Details
Novartis Investigative Site Seoul 03080 South Korea Details
Novartis Investigative Site Seoul 03722 South Korea Details
Novartis Investigative Site Seoul 06351 South Korea Details
Novartis Investigative Site Seville Andalusia 41009 Spain Details
Novartis Investigative Site Donostia / San Sebastian Basque Country 20080 Spain Details
Novartis Investigative Site Pamplona Navarre 31008 Spain Details
Novartis Investigative Site Madrid 28050 Spain Details
Novartis Investigative Site Madrid 28222 Spain Details
Novartis Investigative Site Taichung 40447 Taiwan Details
Novartis Investigative Site Taipei 110 Taiwan Details
Novartis Investigative Site Taoyuan District 33305 Taiwan Details
Novartis Investigative Site Hat Yai Changwat Songkhla 90110 Thailand Details
Novartis Investigative Site Bangkok THA 10330 Thailand Details
Novartis Investigative Site Bangkok 10700 Thailand Details
Novartis Investigative Site Talas / Kayseri 38039 Turkey (Türkiye) Details
Novartis Investigative Site Metropolitan Borough of Wirral Merseyside CH63 4JY United Kingdom Details
Novartis Investigative Site Newcastle upon Tyne Newcastle NE7 7DN United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field